Stockscreener 앱 받기
69.86
3.49%
-2.53
전일 마감가:
$72.39
열려 있는:
$71.91
하루 거래량:
3.39M
Relative Volume:
0.67
시가총액:
$9.10B
수익:
$638.78M
순이익/손실:
$-22.66M
주가수익비율:
-400.57
EPS:
-0.1744
순현금흐름:
$122.18M
1주 성능:
-13.38%
1개월 성능:
-3.88%
6개월 성능:
+176.78%
1년 성능:
+464.30%
1일 변동 폭
$67.52
$73.99
1주일 범위
$67.52
$80.47
52주 변동 폭
$11.80
$102.81
10X 제노믹스 Stock (TXG) Company Profile
명칭
10 X Genomics Inc
전화
(925) 401-7300
주소
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
Compare TXG vs ABT, MDT, SYK, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TXG
10 X Genomics Inc
|
69.86 | 9.10B | 638.78M | -22.66M | 122.18M | -0.1744 |
ABT
Abbott Laboratories
|
104.89 | 181.50B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
94.75 | 121.20B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
294.66 | 113.02B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
44.39 | 64.33B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.60 | 49.92B | 6.30B | 1.07B | 1.09B | 1.8406 |
10X 제노믹스 Stock (TXG) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-09-28 | 개시 | Argus | Buy |
| 2026-09-09 | 재개 | UBS | Neutral |
| 2026-09-01 | 개시 | RBC Capital Mkts | Sector Perform |
| 2026-03-31 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2025-12-11 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-12-02 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-09-11 | 개시 | Piper Sandler | Neutral |
| 2025-02-13 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-09-03 | 개시 | Leerink Partners | Outperform |
| 2024-07-22 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-07-18 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-07-10 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2024-06-27 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-06-03 | 재개 | Jefferies | Hold |
| 2024-05-01 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2023-12-14 | 개시 | Guggenheim | Buy |
| 2023-12-13 | 개시 | Wolfe Research | Outperform |
| 2023-12-12 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2023-07-05 | 재개 | JP Morgan | Overweight |
| 2023-05-10 | 개시 | Barclays | Overweight |
| 2023-03-31 | 개시 | Stephens | Overweight |
| 2023-02-02 | 개시 | UBS | Neutral |
| 2022-12-14 | 개시 | Deutsche Bank | Buy |
| 2022-08-18 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-07-25 | 개시 | Canaccord Genuity | Buy |
| 2022-07-15 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-07-15 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2021-10-15 | 재개 | Cowen | Outperform |
| 2021-09-14 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-03-15 | 개시 | William Blair | Outperform |
| 2020-12-02 | 개시 | Goldman | Neutral |
| 2020-09-09 | 개시 | Morgan Stanley | Overweight |
| 2020-07-10 | 개시 | Stifel | Buy |
| 2020-03-05 | 개시 | Guggenheim | Buy |
| 2020-01-07 | 개시 | Citigroup | Buy |
| 2019-10-07 | 개시 | BofA/Merrill | Buy |
| 2019-10-07 | 개시 | Cowen | Outperform |
| 2019-10-07 | 개시 | JP Morgan | Overweight |
| 2019-09-24 | 개시 | Evercore ISI | Outperform |
모두보기
10X 제노믹스 주식(TXG)의 최신 뉴스
10x Genomics & Fred Hutch Join Forces on Cancer Biomarker Research - Zacks Investment Research
ARK and Catherine D. Wood report ownership above 5% in 10x Genomics (TXG). - Stock Titan
Global Microfluidics Market by Product Type, Application, End User, and Region, 2026-2036 | $48.04 Billion Opportunity Driven by Point-of-Care Diagnostics and Automation - GlobeNewswire Inc.
10x Genomics Begins Atera Shipments as Spatial Biology Demand Rises - Zacks Investment Research
10x genomics director Shehnaaz Suliman sells $464,667 in stock - Investing.com
Form 4 10X Genomics Inc For: 24 September By Investing.com - Investing.com India
10x genomics director Shehnaaz Suliman sells $464,667 in stock By Investing.com - Investing.com Canada
Form 4 10X Genomics Inc For: 24 September By Investing.com - Investing.com UK
10x genomics director Shehnaaz Suliman sells $464,667 in stock By Investing.com - Investing.com UK
Under a trading plan, a 10x Genomics (TXG) director sells 5,723 shares in five transactions. - Stock Titan
At $77.75 to $82.53 a share, 10x Genomics (TXG) CEO made five sales under a trading plan. - Stock Titan
5,723 10x Genomics (NASDAQ: TXG) shares set for Rule 144 sale - Stock Titan
Korea's Lunit announces collaboration with 10x Genomics for AI-enabled pathology analysis of cancer - BioSpectrum Asia
Moderna, 10x Genomics, Oscar Health, and Novavax Shares Are Soaring, What You Need To Know - Yahoo Finance
10x Genomics (TXG) CFO Adam Taich Sells 46,388 Shares - GuruFocus
10x genomics CFO Adam Taich disposes of $2.99 million in company stock - Investing.com Nigeria
10x genomics CFO Adam Taich disposes of $2.99 million in company stock - Investing.com
10x Genomics Inc (TXG) Shares Surge 3.3% -- What GF Score of 56 Tells Investors - GuruFocus
10x genomics CFO Adam Taich disposes of $2.99 million in company stock - Investing.com
10x Genomics (TXG) CFO sells shares under preset trading plan - Stock Titan
Korea's Lunit announces collaboration with 10x Genomics for AI-enabled pathology analysis of cancer - BioSpectrum Asia
Korea's Lunit announces collaboration with 10x Genomics for AI-enabled pathology analysis of cancer - BioSpectrum Asia
10x Genomics CFO Adam Taich sells USD 2.99 million in common shares - Bitget
10x genomics CFO Adam Taich disposes of $2.99 million in company stock - Investing.com UK
10x Genomics Insider Sold Shares Worth $2,995,470, According to a Recent SEC Filing - Yahoo Finance
10x Genomics to Use Lunit’s AI-Powered Pathology Platform for Oncology Biomarker Discovery - GenomeWeb
AI will pair tissue scans with molecular maps in cancer studies - Stock Titan
10x genomics director Stuelpnagel sells $1.2 million in shares By Investing.com - Investing.com Australia
10x Genomics (NASDAQ: TXG) executive plans multimillion-dollar stock sale - Stock Titan
10x Genomics Insider John R. Stuelpnagel Sells 20,000 Shares Between $60.66 and $62.61 on September 3, 2026 (NASDAQ: TXG) - kalkinemedia.com
10x Genomics stock hits 52-week high at 66.95 USD By Investing.com - Investing.com South Africa
10x Genomics Insider Sold Shares Worth $1,235,072, According to a Recent SEC Filing - Yahoo Finance
Macrogen to offer 10x Genomics spatial biology platform in Asia first - Korea Biomedical Review
10x genomics director Stuelpnagel sells $1.2 million in shares - Investing.com
10x Genomics Inc (TXG) Stock Up 4.7% but GF Value Says Overvalued -- GF Score: 56/100 - GuruFocus
10x Genomics (TXG) director offloads 20,000 shares in open-market trades - Stock Titan
T. Rowe Price reports 10%+ holding in 10x Genomics (TXG) - Stock Titan
Stifel reiterates Buy rating on 10X Genomics stock - investing.com
10x Genomics Director Sold Shares Worth Over $1.2M - TradingView
10X Genomics Inc (TXG) Key Financial Ratios – Valuation, Profitability & More - Value Research
10x Genomics (TXG) CEO holds 1,075,249 shares after 100-share gift - Stock Titan
Founder trust at 10x Genomics (NASDAQ: TXG) moves to sell 20,000 shares - Stock Titan
10x Genomics Rallies 84% in 3 Months: Is There More Upside Ahead? - finance.yahoo.com
TXG Stock Price and Chart — NASDAQ:TXG - TradingView
A Look at 10x Genomics Inc (TXG) After 4.0% Decline -- GF Value $18.36 vs Price $60.00 - GuruFocus
RBC Capital initiates 10X Genomics stock with Sector Perform rating - investing.com
10X GENOMICS, INC. : RBC INITIATES COVERAGE WITH SECTOR PERFORM RATING; TARGET PRICE $70 - Bitget
10X GENOMICS, INC. : RBC INITIATES COVERAGE WITH SECTOR PERFORM RATING; TARGET PRICE $70 - Bitget
Jury Awards 10x Genomics Millions in Patent Lawsuit Against Qiagen Unit - Benzinga
TXG Stock Down Despite Patent Verdict Win Against Parse Biosciences - TradingView
10X 제노믹스 (TXG) 재무 분석
매출
순이익
현금흐름
주당 순 이익
10X 제노믹스 주식 (TXG) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Saxonov Serge | Chief Executive Officer |
Sep 22 '26 |
Sale |
81.22 |
25,000 |
2,030,562 |
1,050,249 |
| Shehnaaz Suliman | Affiliate |
Sep 22 '26 |
Proposed Sale |
79.10 |
5,723 |
452,689 |
0 |
| Taich Adam | Chief Financial Officer |
Sep 09 '26 |
Sale |
64.57 |
46,388 |
2,995,470 |
316,344 |
| ADAM TAICH | Officer |
Sep 09 '26 |
Proposed Sale |
64.57 |
46,388 |
2,995,470 |
0 |
| STUELPNAGEL JOHN R | Director |
Sep 03 '26 |
Sale |
61.75 |
20,000 |
1,235,072 |
328,436 |
| STUELPNAGEL JOHN R | Director |
Sep 03 '26 |
Proposed Sale |
61.75 |
20,000 |
1,235,046 |
0 |
| Serge Saxonov | Director, CEO |
Aug 26 '26 |
Proposed Sale |
62.18 |
35,486 |
2,206,654 |
0 |
| Saxonov Serge | Chief Executive Officer |
Aug 26 '26 |
Sale |
63.69 |
10,486 |
667,901 |
1,075,349 |
| SULIMAN SHEHNAAZ | Director |
Aug 24 '26 |
Sale |
63.65 |
2,207 |
140,478 |
29,515 |
| Taich Adam | Officer |
Aug 24 '26 |
Proposed Sale |
65.12 |
16,614 |
1,081,904 |
0 |
3.05%
1.68%
자본화:
|
볼륨(24시간):